Home | Structured Search | Drug Resource
Find: within
Hypothermia > Non-drug Therapy Author: Dmitri Guvakov, MD, PhD; Stuart Weiss, MD, PhD; Albert Cheung, MD
Module updated - 2009-05-21
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Patients with moderate to severe hypothermia should be handled gently because sudden movements or manipulations (endotracheal intubation, suctioning, lifting) can trigger malignant arrhythmias.
  • Removal of wet clothing decreases conduction heat away from the patient.
  • Transportation to a medical center provides access to advanced medical care and equipment.
  • Warm intravenous fluids (normal saline with 5% dextrose or one-half normal saline with dextrose for hypernatremia) are used for the treatment of hypovolemia and decreased blood viscosity.
  • The general approach to treat hypothermia is to use an active rewarming strategy, which may include forced-air warming blankets, circulating-water mattresses, electric blankets, radiant warmers, warm intravenous fluids, peritoneal lavage, extracorporeal rewarming (veno-venous or arterial-venous bypass), gastric lavage, or thoracic lavage.

Evidence:

  • Rough movements or transportation of the hypothermia victim can provoke severe arrhythmias and ventricular fibrillation. Knowledge of the pathophysiology of hypothermia allows for early diagnosis and initiation of therapy to limit morbidity (37; 112).
  • Studies of hypothermic trauma victims and volunteer subjects show the superiority of active rewarming versus passive rewarming (i.e., insulation), significantly reducing the volume of fluid needed for resuscitation as well as short-term mortality (145; 146; 147).

Comments:

  • In trauma patients, hypothermia correlates with the severity of injury but is independently associated with worse outcomes. In one series, mortality in patients with core temperatures <34°C (93.2°F) was 40% compared to 7% for those with core temperatures >=34°C (93.2°F) (148).

FAQs
Albert Cheung, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Dmitri Guvakov, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Stuart Weiss, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Wenjun Zhou Martini, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.